Literature DB >> 19563721

Refining the role of antiplatelet therapy for atrial fibrillation.

Jai Singh1, Deepak L Bhatt.   

Abstract

Entities:  

Year:  2009        PMID： 19563721     DOI： 10.1007/s11886-009-0034-8

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


× No keyword cloud information.
  8 in total

1.  ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.

Authors:  Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; Jean-Yves Le Heuzey; G Neal Kay; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffery L Anderson; Elliott M Antman; Jonathan L Halperin; Sharon Ann Hunt; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; A John Camm; Veronica Dean; Jaap W Deckers; Catherine Despres; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; Joao Morais; Ady Osterspey; Juan Luis Tamargo; José Luis Zamorano
Journal:  Circulation       Date:  2006-08-15       Impact factor: 29.690

2.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.

Authors:  S Connolly; J Pogue; R Hart; M Pfeffer; S Hohnloser; S Chrolavicius; M Pfeffer; S Hohnloser; S Yusuf
Journal:  Lancet       Date:  2006-06-10       Impact factor: 79.321

3.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

4.  Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.

Authors:  Stuart J Connolly; Janice Pogue; John Eikelboom; Gregory Flaker; Patrick Commerford; Maria Grazia Franzosi; Jeffrey S Healey; Salim Yusuf
Journal:  Circulation       Date:  2008-10-27       Impact factor: 29.690

5.  Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.

Authors:  Brian F Gage; Carl van Walraven; Lesly Pearce; Robert G Hart; Peter J Koudstaal; B S P Boode; Palle Petersen
Journal:  Circulation       Date:  2004-10-11       Impact factor: 29.690

6.  Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.

Authors:  Robert G Hart; Deepak L Bhatt; Werner Hacke; Keith A A Fox; Graeme J Hankey; Peter B Berger; Tingfei Hu; Eric J Topol
Journal:  Cerebrovasc Dis       Date:  2008-02-27       Impact factor: 2.762

7.  Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis.

Authors:  Shinya Goto; Deepak L Bhatt; Joachim Röther; Mark Alberts; Michael D Hill; Yasuo Ikeda; Shinichiro Uchiyama; Ralph D'Agostino; E Magnus Ohman; Chiau-Suong Liau; Alan T Hirsch; Jean-Louis Mas; Peter W F Wilson; Ramón Corbalán; Franz Aichner; P Gabriel Steg
Journal:  Am Heart J       Date:  2008-09-23       Impact factor: 4.749

8.  Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).

Authors:  Jeff S Healey; Robert G Hart; Janice Pogue; Marc A Pfeffer; Stefan H Hohnloser; Raffaele De Caterina; Greg Flaker; Salim Yusuf; Stuart J Connolly
Journal:  Stroke       Date:  2008-03-06       Impact factor: 7.914
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.